Anti-tumor activities have been observed using strategies that antagonize the interplay of Wnt-related receptors and ligands, including the use of mAbs against LRP6, Wnt1, Wnt2, Fzd7, Fzd10, or LGR519,42–46 and Wnt-binding decoy receptors47–51. Here, WNT1 is linked to neoplasm.